Regeneron(REGN) Prnewswire·2025-01-14 10:45Lawsuit Overview - Levi & Korsinsky, LLP has notified investors of a class action securities lawsuit against Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) [1] - The lawsuit aims to recover losses for Regeneron investors affected by alleged securities fraud between November 2, 2023 and October 30, 2024 [1] Allegations - Regeneron allegedly paid credit card fees to distributors on the condition that they did not charge Eylea customers more for using credit cards [2] - These payments subsidized the prices customers paid when using credit cards to purchase Eylea [2] - As a result, Regeneron offered price concessions that lowered Eylea's selling price [2] - The price concessions provided a competitive advantage due to retina practices' sensitivity to higher prices when purchasing anti-VEGF medications with credit cards [2] - Regeneron allegedly boosted reported Eylea sales misleadingly [2] - The company failed to report its payment of credit card fees as price concessions, thereby overstating the ASP reported to federal agencies and violating the False Claims Act [2] - Defendants' positive statements about the company's business, operations, and prospects were allegedly materially misleading and/or lacked a reasonable basis [2] Next Steps - Investors who suffered losses in Regeneron during the relevant time frame have until March 10, 2025 to request the Court appoint them as lead plaintiff [4] - Class members may be entitled to compensation without payment of any out-of-pocket costs or fees [4] Levi & Korsinsky's Track Record - Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders [5] - The firm has a track record of winning high-stakes cases and extensive expertise in representing investors in complex securities litigation [5] - Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States for seven consecutive years [5]